Cite
HARVARD Citation
Arai, H. et al. (n.d.). P1–338: Safety, tolerability and immunogenicity of an immunotherapeutic vaccine (vanutide cridificar [ACC‐001]) and the QS‐21 adjuvant in Japanese individuals with mild‐to‐moderate Alzheimer's disease: A phase IIa, multicenter, randomized, adjuvant and placebo clinical trial. Alzheimer's & dementia. p. P282. [Online].